Study on Radiotherapy and Pembrolizumab for People with Adrenocortical Carcinoma

Inclusion Criteria

• Be willing and able to provide written consent to participate in the trial.
• Be 15 years or older.
• Have confirmed advanced adrenocortical carcinoma (ACC) with symptoms affecting the liver.
• Have a performance status that allows for daily activities, as measured by specific health scales.
• Have measurable cancer based on standard criteria.
• Have cancer that has spread beyond the liver.
• Agree to provide a sample of previous tumor tissue for research, if available.
• Have adequate organ function based on specific blood tests.
• Women of childbearing age must have a negative pregnancy test before starting treatment and agree to use two forms of birth control or be surgically sterile during the study and for 120 days after the last dose.
• Men must agree to use effective contraception during the study and for 120 days after the last dose.

Exclusion Criteria

• Currently participating in another study or have used an investigational drug or device within 4 weeks before starting this study.
• Have had radiation therapy to the same area as the study cancer that would overlap with the study treatment.
• Have an immune system deficiency or are taking medications that suppress the immune system within 7 days before starting the study.
• Have received a monoclonal antibody treatment within 4 weeks before starting the study and have not recovered from any side effects.
• Have had chemotherapy or targeted therapy within 2 weeks before starting the study and have not recovered from any side effects.
• Have another progressing cancer that requires treatment, except for certain skin cancers or cervical cancer that has been treated.
• Have active cancer in the brain or spinal cord, unless previously treated and stable.
• Have an active autoimmune disease requiring treatment within the past 3 months.
• Have lung disease or a history of lung inflammation that required steroids.
• Have an active infection requiring treatment.
• Have any condition or history that might interfere with the study or is not in the best interest of the participant.
• Have psychiatric or substance abuse issues that would interfere with the study.
• Are pregnant or breastfeeding, or planning to conceive or father a child during the study and for 120 days after.
• Have received prior therapy targeting specific immune pathways.
• Have a known history of HIV.
• Have active Hepatitis B or C.
• Have received a live vaccine within 30 days before starting the study.